6 [20] Y. Arinobu, S. Mizuno, Y. Chong et al., “Reciprocal activation of GATA-1 and PU.1 marks initial speciﬁcation of hemato- poietic stem cells into myeloerythroid and myelolymphoid lineages,” Cell Stem Cell, vol. 1, no. 4, pp. 416–427, 2007. [21] C. J. Spooner, J. X. Cheng, E. Pujadas, P. Laslo, and H. Singh, “A recurrent network involving the transcription factors PU.1 and Gﬁ1 orchestrates innate and adaptive immune cell fates,” Immunity, vol. 31, no. 4, pp. 576–586, 2009. [22] M. B. Kamath, I. B. Houston, A. J. Janovski et al., “Dose- dependent repression of T-cell and natural killer cell genes by PU.1 enforces myeloid and B-cell identity,” Leukemia, vol. 22, no. 6, pp. 1214–1225, 2008. [23] R. Pop, J. R. Shearstone, Q. Shen et al., “A key commitment step in erythropoiesis is synchronized with the cell cycle clock through mutual inhibition between PU.1 and S-phase pro- gression,” PLoS Biology, vol. 8, no. 9, Article ID e1000484, 2010. [24] J. Starck, A. Doubeikovski, S. Sarrazin et al., “Spi-1/PU.1 is a positive regulator of the Fli-1 gene involved in inhibition of erythroid diﬀerentiation in friend erythroleukemic cell lines,” Molecular and Cellular Biology, vol. 19, no. 1, pp. 121–135, 1999. [25] K. S. Choe, O. Ujhelly, S. N. Wontakal, and A. I. Skoultchi, “PU.1 directly regulates cdk6 gene expression, linking the cell proliferation and diﬀerentiation programs in erythroid cells,” Journal of Biological Chemistry, vol. 285, no. 5, pp. 3044–3052, 2010. [26] G. Rao, N. Rekhtman, G. Cheng, T. Krasikov, and A. I. Skoul- tchi, “Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal diﬀerentiation,” Oncogene, vol. 14, no. 1, pp. 123–131, 1997. [27] M. Papetti and A. I. Skoultchi, “Reprogramming leukemia cells to terminal diﬀerentiation and growth arrest by RNA interference of PU.1,” Molecular Cancer Research, vol. 5, no. 10, pp. 1053–1062, 2007. [28] O. Atar and B. Z. Levi, “PU.1 silencing leads to terminal dif- ferentiation of erythroleukemia cells,” Biochemical and Bio- physical Research Communications, vol. 329, no. 4, pp. 1288– 1292, 2005. [29] T. Yamada, N. Kondoh, M. Matsumoto, M. Yoshida, A. Maekawa, and T. Oikawa, “Overexpression of PU.1 induces growth and diﬀerentiation inhibition and apoptotic cell death in murine erythroleukemia cells,” Blood, vol. 89, no. 4, pp. 1383–1393, 1997. [30] I. Matushansky, F. Radparvar, and A. I. Skoultchi, “CDK6 blocks diﬀerentiation: coupling cell proliferation to the block to diﬀerentiation in leukemic cells,” Oncogene, vol. 22, no. 27, pp. 4143–4149, 2003. [31] P. Burda, N. Curik, J. Kokavec et al., “PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leu- kemia diﬀerentiation,” Molecular Cancer Research, vol. 7, no. 10, pp. 1693–1703, 2009. [32] N. Rekhtman, F. Radparvar, T. Evans, and A. I. Skoultchi, “Direct interaction of hematopoietic transcription factors PU. 1 and GATA- 1: functional antagonism in erythroid cells,” Genes and Development, vol. 13, no. 11, pp. 1398–1411, 1999. [33] P. Zhang, X. Zhang, A. Iwama et al., “PU.1 inhibits GATA- 1 function and erythroid diﬀerentiation by blocking GATA-1 DNA binding,” Blood, vol. 96, no. 8, pp. 2641–2648, 2000. [34] P. Zhang, G. Behre, J. Pan et al., “Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1,” Pro- ceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 15, pp. 8705–8710, 1999. International Journal of Cell Biology [35] I. B. Houston, M. B. Kamath, B. L. Schweitzer, T. M. Chlon, and R. P. DeKoter, “Reduction in PU.1 activity results in a block to B-cell development, abnormal myeloid proliferation, and neonatal lethality,” Experimental Hematology, vol. 35, no. 7, pp. 1056–1068, 2007. [36] S. Hohaus, M. S. Petrovick, M. T. Voso, Z. Sun, D. E. Zhang, and D. G. Tenen, “PU.1 (Spi-1) and C/EBPα regulate expression of the granulocyte-macrophage colony-stimulating factor receptor α gene,” Molecular and Cellular Biology, vol. 15, no. 10, pp. 5830–5845, 1995. [37] D. E. Zhang, C. J. Hetherington, H. M. Chen, and D. G. Tenen, “The macrophage transcription factor PU.1 directs tissue- speciﬁc expression of the macrophage colony-stimulating factor receptor,” Molecular and Cellular Biology, vol. 14, no. 1, pp. 373–381, 1994. [38] R. Dahl, J. C. Walsh, D. Lancki et al., “Regulation of macrophage and neutrophil cell fates by the PU.1: C/EBPα ratio and granulocyte colony-stimulating factor,” Nature Immunology, vol. 4, no. 10, pp. 1029–1036, 2003. [39] P. Laslo, C. J. Spooner, A. Warmﬂash et al., “Multilin- eage transcriptional priming and determination of alternate hematopoietic cell fates,” Cell, vol. 126, no. 4, pp. 755–766, 2006. [40] C. J. Hu, S. Rao, D. L. Ramirez-Bergeron et al., “PU.1/Spi- B regulation of c-rel is essential for mature B cell survival,” Immunity, vol. 15, no. 4, pp. 545–555, 2001. [41] G. H. Su, H. S. Ip, B. S. Cobb, M. M. Lu, H. M. Chen, and M. C. Simon, “The Ets protein Spi-B is expressed exclusively in B cells and T cells during development,” Journal of Experimental Medicine, vol. 184, no. 1, pp. 203–214, 1996. [42] M. K. Anderson, A. H. Weiss, G. Hernandez-Hoyos, C. J. Dionne, and E. V. Rothenberg, “Constitutive expression of PU.1 in fetal hematopoietic progenitors blocks T cell development at the pro-T cell stage,” Immunity, vol. 16, no. 2, pp. 285–296, 2002. [43] B. U. Mueller, T. Pabst, M. Osato et al., “Heterozygous PU.1 mutations are associated with acute myeloid leukemia,” Blood, vol. 100, no. 3, pp. 998–1007, 2002. [44] P. Burda, P. Laslo, and T. Stopka, “The role of PU.1 and GATA- 1 transcription factors during normal and leukemogenic hematopoiesis,” Leukemia, vol. 24, no. 7, pp. 1249–1257, 2010. [45] N. Suraweera, E. Meijne, J. Moody et al., “Mutations of the PU.1 Ets domain are speciﬁcally associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia,” Oncogene, vol. 24, no. 22, pp. 3678–3683, 2005. [46] V. Vegesna, S. Takeuchi, W. K. Hofmann et al., “C/EBP- β, C/EBP-δ, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies,” Leukemia Research, vol. 26, no. 5, pp. 451–457, 2002. [47] T. J. Ley, P. J. Minx, M. J. Walter et al., “A pilot study of high- throughput, sequence-based mutational proﬁling of primary human acute myeloid leukemia cell genomes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 24, pp. 14275–14280, 2003.